IL23A and psoriasis: Our present study has highlighted the possibility of using rhIL-23R-CHR/Fc to treat psoriasis, and further demonstrated that rhIL-23R-CHR/Fc could improve IMQ-induced psoriasis through not only the inhibition of the adaptive immunity of the IL-23/Th17 pathway but also the inhibition of the innate immunity of ILC3 activation, which provides a new direction for drug design for autoimmune diseases.